Polymer use in Preservation of Tissue Perfusion to Address Sepsis

灌流医疗公司正在商业化一种新的流水线产品，称为聚乙二醇-20k IV溶液。这个 该公司认为，这可能是第一种直接治疗脓毒症致命并发症的疗法， 因此，支持关于该病基本机制的新思维。脓毒症或败血症 综合征导致一系列疾病，在中国有170万人出现的频率 美国每年有超过27万人死于感染性休克。败血症，由 直接细菌感染或由受损内脏的内毒素(LPS)泄漏 循环，产生一系列复杂的免疫和非免疫反应。 这些最终会导致多系统器官衰竭和死亡。没有任何药物 专门用于缓解感染和来源以外的任何败血症的潜在基础 控制力。该公司声称，在早期恢复组织灌流的组合 脓毒症和分解内皮细胞糖萼，将是一种全新的方法， 防止恶性循环和随之而来的致命的多器官衰竭。STTR涉及两个方面 目标。AIM 1将确定脂多糖诱导的和多菌类药物的区域毛细血管灌注 腹膜炎所致感染性休克及聚乙二醇20K复苏的影响研究人员将 试图证明与内毒素或细菌性脓毒症相关的巨大血流灌注缺陷 在脓毒症早期恢复灌流可避免 通过保存生命组织的氧交换来减少多器官衰竭和死亡率。目标2将 确定脓毒症时糖萼的完整性以及聚乙二醇20K复苏的效果。这个 团队打算证明，PEG-20k非特异性地绑定到并保护/重建 脓毒症和多器官衰竭时内皮细胞糖基化反应，这限制了继发性细胞 炎症性终末器官损伤。在这项研究结束时，该公司将进行概念验证 数据显示感染性休克死亡率和器官衰竭的主要决定因素是次要的。 对于严重的生命组织灌流不良，早期使用聚乙二醇20K纠正可以避免 破坏性的下游后果导致危重疾病和死亡。如果成功，则 解决方案将被证明是有效的，有两种机制来解决脓毒症-其中之一 这将使聚乙二醇20k成为强有力的候选治疗产品。

Perfusion Medical is commercializing a novel pipeline product called PEG-20k IV Solution. The company believes this may be the first therapeutic to directly treat lethal complications of sepsis, and as such, support new thinking on the basic mechanisms of the disease. Sepsis or septic syndrome leads to a spectrum of illnesses and occurs at a frequency of 1.7 million people in the US each year and septic shock kills over 270,000 Americans each year. Sepsis, caused by direct bacterial infection or by leak of lipopolysaccharide (LPS) from a compromised splanchnic circulation, produces a complex cascade of immunological and non-immunological reactions. These ultimately lead to multiple systems organ failure and death. There are no medications specifically used to mitigate any underlying basis for sepsis other than infection and source control. The company asserts that the combination of restoration of tissue perfusion in early sepsis and breaking down endothelial cell glycocalyx, will be a radically new approach that prevents the vicious cycle and the attendant fatal multiple organ failure. The STTR involves two AIMS. AIM 1 will determine regional capillary perfusion in LPS-induced and polymicrobial peritonitis-induced septic shock and the effects of PEG-20k resuscitation. The researchers will seek to demonstrate that the massive perfusion defect associated with LPS or bacterial sepsis is reversed by PEG-20k IV solution and that restoring perfusion in early course of sepsis averts multiple organ failure and mortality by preserving vital tissue oxygen exchange. AIM 2 will determine the integrity of the glycocalyx in sepsis and the effect of PEG-20k resuscitation. The team intends to demonstrate that PEG-20k nonspecifically binds to and protects / rebuilds the endothelial glycocalyx during sepsis and multiple organ failure, which limits secondary cellular inflammatory end-organ injury. At the end of this study, the company will have proof-of-concept data showing that a major determinant of septic shock mortality and organ failure is secondary to severe malperfusion of vital tissues and that early correction with PEG-20k can avert devastating downstream consequences leading to critical illness and death. If successful, the solution will be shown to be effective with two mechanisms of addressing sepsis – either of which will make PEG-20k a strong candidate as a therapeutic product.